Skip to main content

Joel Tepper, MD, FASTRO

Hector MacLean Distinguished Professor of Cancer Research

Education

  • Research Fellowship: American Cancer Society Junior Fellow (1975-1976)
  • Clinical Fellow, Radiation Therapy, Massachusetts General Hospital, Boston, MA (1976-77)
  • Residency in Radiation Therapy, Massachusetts General Hospital, Boston, MA (1973-76)
  • MD Washington University School of Medicine, St. Louis, MO (1972)
  • BS Electrical Engineering, Massachusetts Institute of Technology, Cambridge, MA (1968)

Certification/Licensure

  • Licensed to practice in North Carolina (1987), Massachusetts (1973)
  • Board Certified in Radiation Therapy by the American Board of Radiology (1976)

Honors

  • ASTRO* President (2002-2003)
  • ASTRO Chairman of the Board (2003-2004)
  • ASTRO Fellow (2006)
  • ASTRO Gold Medal (2008)
  • ASCO** Board of Directors (2007-2010)
  • ASCO Fellow (2011)
  • AAAS*** Fellow (2013)
  • Berryhill Lecturer

ASTRO*: American Society for Radiation Oncology
ASCO**: American Society of Clinical Oncology
AAAS***: American Association for the Advancement of Science

Major Research Interests

  • Gastrointestinal neoplasms
  • Combined modality therapy
  • Soft tissue sarcomas
  • Nanotechnology and cancer

Grants (Active)

  • 2010 – present: Co-Director of the NCI-funded Carolina Center for Cancer Nanotechnology Excellence

Editorships

  • 1983: Gunderson LL, Tepper JE, eds. Intraoperative + external beam irradiation.  In: Current Problems in Cancer, Vol. VII, Yearbook Medical Publishers, Inc., Chicago, London.
  • 1991-present: Tepper, J. Ed., Seminars in Radiation Oncology. Elsevier, New York.
  • 2000, 2007, 2011, 2016, 2019: Gunderson LL,Tepper JE, eds. Clinical Radiation Oncology. Elsevier, New York.
  • 2002, 2007: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, eds. Gastrointestinal Oncology: Principles and Practice. Lippincott Williams & Wilkins, Philadelphia.
  • 2014, 2019: Niederhuber J, Armitage J, Doroshow J, Kastan M and Tepper J, Eds. Clinical Oncology, Elsevier, New York.

Peer-Reviewed Publications (Recent)

  • Byrne JD, R Jajja MN, O’Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med. 2015 Feb 4;7(273):273ra14.
  • Meyerhardt JA, Tepper JE, Venook AP. Special series: Advances in GI cancer. J Clin Oncol. 2015 Jun 1;33(16):1717-1720.
  • Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, Hayes N, Weiss J, GrilleyOlson J, Zanation A, Hackman T, Funkhouser W, Sheets N, Weissler M, Mendenhall W. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):976-985.
  • Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ. CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1α. Cancer Res. 2017 Jan 1;77(1):112-122.
  • Koong AC, Tepper JE. Introduction. Semin Radiat Oncol. 2017 Jul;27(3):189.
  • VanderWalde NA, Deal AM, Comitz E, Stravers L, Muss H, Reeve BB, Basch E, Tepper J, Chera B. Geriatric assessment as a predictor of tolerance, quality of life, and outcomes in older patients with head and neck cancers and lung cancers receiving radiation therapy.  Int J Radiat Oncol Biol Phys 2017 Jul 15;98(4):850-857. PMID: 28258889.
  • Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017 Sep;12(9):877-882.
  • Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13.
  • Tepper JE. Ethics in clinical care. Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):250-254.
  • Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O’Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: Results from CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10;35(32):3671-3677.
  • Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018 Mar;126(3):527-533.
  • Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ. Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds. Nat Biomed Eng. 2018 Jun;2(6):443-452.
  • Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE, Hayes DN, Zanation A, Hackman TG, Patel S, Sheets N, Weissler MC, Mendenhall WM. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. 2018 Jun 1;124(11):2347-2354.
  • Myung JH, Eblan MJ, Caster JM, Park SJ, Poellmann MJ, Wang K, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Tepper JE, Chera BS, Wang AZ, Hong S.  Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture.  Clin Cancer Res 2018 Jun 1;24(11):2539-2547.
  • Tepper JE. Oncologist, cancer patient, oncologist.  Pract Radiat Oncol. 2018 Sep-Oct;8(5):295-296.
  • Marks LB, Tepper JE.”Wisest Is He Who Knows What He Does Not Know.” Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):687-690.
  • Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O’Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ.Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine. 2019 Mar 8;18:189-195.